Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Merck & Co takes IRA legal action; notes from BIO Day 1; stories from ASCO around ImmunoGen’s ovarian cancer candidate and Servier’s progress in glioma; and the future of AI in pharma.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 9 June 2023, including: Merck & Co., Inc. takes IRA legal action; notes from BIO Day 1; stories from ASCO around ImmunoGen, Inc.’s ovarian cancer candidate and Servier’s progress in glioma; and the future of AI in pharma.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Merck & Co. Files First IRA Suit, Signaling Industry Is Ready To Fight" - Scrip, 6 Jun, 2023.)
(Also see "BIO Notebook: GSK’s Walmsley On M&A, Merck On How Falling Valuations Are Affecting Deals" - Scrip, 5 Jun, 2023.)
(Also see "ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use" - Scrip, 4 Jun, 2023.)
(Also see "ASCO 2023 - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO" - Scrip, 4 Jun, 2023.)
(Also see "ChatGPT Unleashed: Generative AI Use Cases Taking Off In Pharma" - Scrip, 6 Jun, 2023.)